Clinical Trial Update: A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a single dose of etavopivat in healthy Chinese participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Thalassemia

Drugs mentioned

• Etavopivat (Etavopivat)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Healthy Volunteers, Sickle Cell Disease | Phase 1 | Status: COMPLETED